Etiology, natural history, management, and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes)

Genetic counseling implications

Henry T. Lynch, Stephen J. Lemon, Beth Karr, Barbara Franklin, Jane F. Lynch, Patrice Watson, Susan Tinley, Caryn Lerman, Christine Carter

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

We estimate that 5-10% of virtually all forms of cancer are due to a primary hereditary etiology. However, a hereditary cancer diagnosis is often missed because the family history of cancer is given short shrift in medical practice. Hereditary nonpolyposis colorectal cancer (HNPCC) certainly fits this estimate, although some studies suggest that a minimum of 2% with a range as high as 10% of the total colorectal cancer burden is due to HNPCC. Mutations in one of the four mismatch repair genes, i.e., hMSH2, hMLH1, hPMS1, and hPMS2, account for about 70% of HNPCC kindreds. Other germ-line mutations are likely to be identified to account for the remainder of HNPCC patients. By far the most common HNPCC mutations involve hMSH2 and hMLH1, with hPMS1 and hPMS2 accounting for only about 3% of such families. Prior to these molecular genetic discoveries, the genetic counselor could only provide the patient with an estimate of a 50% likelihood of manifesting HNPCC based on the counselee having one or more first-degree relatives manifesting syndrome cancers in their direct genetic lineage. Because DNA testing has become available in families with known mutations, we have provided pretest group education in the form of a family information service with intensive education about the natural history, genetic risk, surveillance, and options for management of HNPCC, as well as discussion of the potential for fear, anxiety, apprehension, and insurance or employer discrimination that might impact on this DNA testing. Following informed consent, these relatives were then counseled on a one-to-one basis. Using DNA-based genetic counseling involving hMSH2 or hMLH1, we have provided this service to four extended HNPCC kindreds. Details of this genetic counseling experience on these four kindreds will be discussed.

Original languageEnglish
Pages (from-to)987-991
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume6
Issue number12
StatePublished - 1997

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
Genetic Counseling
Natural History
Molecular Biology
Mutation
DNA
Neoplasms
Education
DNA Mismatch Repair
Information Services
Germ-Line Mutation
Insurance
Informed Consent
Fear
Colorectal Neoplasms
Anxiety

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology

Cite this

Etiology, natural history, management, and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes) : Genetic counseling implications. / Lynch, Henry T.; Lemon, Stephen J.; Karr, Beth; Franklin, Barbara; Lynch, Jane F.; Watson, Patrice; Tinley, Susan; Lerman, Caryn; Carter, Christine.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 6, No. 12, 1997, p. 987-991.

Research output: Contribution to journalArticle

Lynch, Henry T. ; Lemon, Stephen J. ; Karr, Beth ; Franklin, Barbara ; Lynch, Jane F. ; Watson, Patrice ; Tinley, Susan ; Lerman, Caryn ; Carter, Christine. / Etiology, natural history, management, and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes) : Genetic counseling implications. In: Cancer Epidemiology Biomarkers and Prevention. 1997 ; Vol. 6, No. 12. pp. 987-991.
@article{021655f7f9334f00b6144b4703e8ab66,
title = "Etiology, natural history, management, and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes): Genetic counseling implications",
abstract = "We estimate that 5-10{\%} of virtually all forms of cancer are due to a primary hereditary etiology. However, a hereditary cancer diagnosis is often missed because the family history of cancer is given short shrift in medical practice. Hereditary nonpolyposis colorectal cancer (HNPCC) certainly fits this estimate, although some studies suggest that a minimum of 2{\%} with a range as high as 10{\%} of the total colorectal cancer burden is due to HNPCC. Mutations in one of the four mismatch repair genes, i.e., hMSH2, hMLH1, hPMS1, and hPMS2, account for about 70{\%} of HNPCC kindreds. Other germ-line mutations are likely to be identified to account for the remainder of HNPCC patients. By far the most common HNPCC mutations involve hMSH2 and hMLH1, with hPMS1 and hPMS2 accounting for only about 3{\%} of such families. Prior to these molecular genetic discoveries, the genetic counselor could only provide the patient with an estimate of a 50{\%} likelihood of manifesting HNPCC based on the counselee having one or more first-degree relatives manifesting syndrome cancers in their direct genetic lineage. Because DNA testing has become available in families with known mutations, we have provided pretest group education in the form of a family information service with intensive education about the natural history, genetic risk, surveillance, and options for management of HNPCC, as well as discussion of the potential for fear, anxiety, apprehension, and insurance or employer discrimination that might impact on this DNA testing. Following informed consent, these relatives were then counseled on a one-to-one basis. Using DNA-based genetic counseling involving hMSH2 or hMLH1, we have provided this service to four extended HNPCC kindreds. Details of this genetic counseling experience on these four kindreds will be discussed.",
author = "Lynch, {Henry T.} and Lemon, {Stephen J.} and Beth Karr and Barbara Franklin and Lynch, {Jane F.} and Patrice Watson and Susan Tinley and Caryn Lerman and Christine Carter",
year = "1997",
language = "English",
volume = "6",
pages = "987--991",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Etiology, natural history, management, and molecular genetics of hereditary nonpolyposis colorectal cancer (Lynch syndromes)

T2 - Genetic counseling implications

AU - Lynch, Henry T.

AU - Lemon, Stephen J.

AU - Karr, Beth

AU - Franklin, Barbara

AU - Lynch, Jane F.

AU - Watson, Patrice

AU - Tinley, Susan

AU - Lerman, Caryn

AU - Carter, Christine

PY - 1997

Y1 - 1997

N2 - We estimate that 5-10% of virtually all forms of cancer are due to a primary hereditary etiology. However, a hereditary cancer diagnosis is often missed because the family history of cancer is given short shrift in medical practice. Hereditary nonpolyposis colorectal cancer (HNPCC) certainly fits this estimate, although some studies suggest that a minimum of 2% with a range as high as 10% of the total colorectal cancer burden is due to HNPCC. Mutations in one of the four mismatch repair genes, i.e., hMSH2, hMLH1, hPMS1, and hPMS2, account for about 70% of HNPCC kindreds. Other germ-line mutations are likely to be identified to account for the remainder of HNPCC patients. By far the most common HNPCC mutations involve hMSH2 and hMLH1, with hPMS1 and hPMS2 accounting for only about 3% of such families. Prior to these molecular genetic discoveries, the genetic counselor could only provide the patient with an estimate of a 50% likelihood of manifesting HNPCC based on the counselee having one or more first-degree relatives manifesting syndrome cancers in their direct genetic lineage. Because DNA testing has become available in families with known mutations, we have provided pretest group education in the form of a family information service with intensive education about the natural history, genetic risk, surveillance, and options for management of HNPCC, as well as discussion of the potential for fear, anxiety, apprehension, and insurance or employer discrimination that might impact on this DNA testing. Following informed consent, these relatives were then counseled on a one-to-one basis. Using DNA-based genetic counseling involving hMSH2 or hMLH1, we have provided this service to four extended HNPCC kindreds. Details of this genetic counseling experience on these four kindreds will be discussed.

AB - We estimate that 5-10% of virtually all forms of cancer are due to a primary hereditary etiology. However, a hereditary cancer diagnosis is often missed because the family history of cancer is given short shrift in medical practice. Hereditary nonpolyposis colorectal cancer (HNPCC) certainly fits this estimate, although some studies suggest that a minimum of 2% with a range as high as 10% of the total colorectal cancer burden is due to HNPCC. Mutations in one of the four mismatch repair genes, i.e., hMSH2, hMLH1, hPMS1, and hPMS2, account for about 70% of HNPCC kindreds. Other germ-line mutations are likely to be identified to account for the remainder of HNPCC patients. By far the most common HNPCC mutations involve hMSH2 and hMLH1, with hPMS1 and hPMS2 accounting for only about 3% of such families. Prior to these molecular genetic discoveries, the genetic counselor could only provide the patient with an estimate of a 50% likelihood of manifesting HNPCC based on the counselee having one or more first-degree relatives manifesting syndrome cancers in their direct genetic lineage. Because DNA testing has become available in families with known mutations, we have provided pretest group education in the form of a family information service with intensive education about the natural history, genetic risk, surveillance, and options for management of HNPCC, as well as discussion of the potential for fear, anxiety, apprehension, and insurance or employer discrimination that might impact on this DNA testing. Following informed consent, these relatives were then counseled on a one-to-one basis. Using DNA-based genetic counseling involving hMSH2 or hMLH1, we have provided this service to four extended HNPCC kindreds. Details of this genetic counseling experience on these four kindreds will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0031470414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031470414&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 987

EP - 991

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -